Physician profile
John E Mendelson
NPI 1891889341
$680.27
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $79.57 · 2021: $12.84.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $270.21 | 2019-2020 | |
| Alkermes, INC. | $167.55 | 2019 | |
| Viiv Healthcare Company | $80.15 | 2019 | |
| Daiichi Sankyo INC. | $55.75 | 2019-2020 | |
| Astellas Pharma US INC | $23.67 | 2019 | |
| Biodelivery Sciences International, INC. | $22.60 | 2019 | |
| Amgen INC. | $17.43 | 2020 | |
| Janssen Biotech, INC. | $15.68 | 2019 | |
| Horizon Therapeutics Plc | $14.39 | 2020 | |
| Abbvie INC. | $12.84 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mendelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.